Semaglutide
A Study of BGM0504 in Early T2DM With Obesity
Novo Nordisk · Phase 3 · Recruiting · Enrollment 372
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| BGM0504 Injection 15 mg | T2D only | 15 mg | 52 | n/r | n/r |
| Semaglutide Injection 1.0 mg | T2D only | 1.0 mg | 52 | n/r | n/r |